Armata Pharmaceuticals Enters Secured Credit Agreement With Innoviva Strategic Opportunities, A Wholly-owned Subsidiary Of Innoviva
Armata Pharmaceuticals Enters Secured Credit Agreement With Innoviva Strategic Opportunities, A Wholly-owned Subsidiary Of Innoviva
Armata Pharmicals 与 Innoviva 的全资子公司 Innoviva Strategic Opportunities 签订担保信贷协议
The gross proceeds to be received by the Company at closing are $35 million before deducting transaction-related expenses. Proceeds from the $35 million new financing transaction will be used to advance the Company's lead therapeutic phage candidates, including AP‐PA02 and AP‐SA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.
在扣除交易相关费用之前，公司在收盘时收到的总收益为3500万美元。这笔3500万美元新融资交易的收益将用于推进公司主要的候选治疗噬菌体，包括针对由以下原因引起的感染的AP‐PA02和AP‐SA02 铜绿假单胞菌 和 金黄色葡萄球菌，分别地。